Healthcare Industry News: HSMN NewsFeed
News Release - August 30, 2021
Zimmer Biomet and Canary Medical Announce FDA De Novo Classification Grant and Authorization to Market the World's First and Only Smart Knee ImplantPersona IQ® Knee Implant Combines ZB's Proven and Trusted Persona® Knee with Canary Medical's Proprietary Implantable canturio™ te Tibial Extension Sensor Technology
Post-operative Gait Metrics to Provide Real World, Objective Patient Data
WARSAW, Ind. and VANCOUVER, BC, Aug. 30, 2021 -- (Healthcare Sales & Marketing Network) -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Canary Medical, a medical data company, today announced U.S. Food and Drug Administration (FDA) De Novo classification grant and authorization to market the tibial extension for Persona IQ®, the world's first and only smart knee cleared by the FDA for total knee replacement surgery. Persona IQ combines Zimmer Biomet's proven and trusted knee implant, Persona® The Personalized Knee®, with Canary Medical's proprietary implantable canturioTM te tibial extension sensor technology that measures and determines range of motion, step count, walking speed and other gait metrics. Persona IQ will work together with Zimmer Biomet's remote care management platform, mymobility® with Apple Watch®, as well as other components of the ZBEdge™ Connected Intelligence Suite.
"We are excited to introduce Persona IQ, the world's first and only smart knee implant, which offers a wealth of objective data to monitor patients' post-operative progress," said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. "As the newest component of ZBEdge, Persona IQ advances our vision of creating a seamlessly connected suite of digital health and robotic technologies to deliver objective data to clinicians throughout the surgical journey. Following a recent expansion of our partnership with Canary Medical, we now expect that Persona IQ will be the first in a broader portfolio of smart implant technologies in various orthopedic surgery applications."
"After almost a decade of development and designation by FDA as a Breakthrough Device, we're proud that our CANARY canturio™ te technology has enabled Zimmer Biomet to debut the world's first smart knee implant. Persona IQ reflects our shared belief that automatic, reliable and accurate data collection and analysis represents the future of orthopedic care," said William L. Hunter, MD, MSC and CEO of Canary Medical. "The launch of Persona IQ marks the start of an exciting, ongoing partnership with Zimmer Biomet designed to innovate smart implant technologies that help joint replacement patients regain and maintain their mobility with confidence."
"Historically, surgeons relied on patient-reported metrics during intermittent post-op follow up visits to assess the quality and pace of recovery from knee replacement surgery. Now, with physiological tools to support remote monitoring technologies like mymobility, and smart implants like Persona IQ, we can actively monitor patient recovery and rely on real-world, objective data to supplement patient care," said Peter Sculco, MD, orthopedic surgeon at Hospital for Special Surgery in New York. "In addition, providing patients with access to their own mobility data will allow them the opportunity to be engaged in their recovery in a new way."
Once surgically implanted in the knee, Persona IQ records and wirelessly transmits a wide range of gait data to a patient's personal base station at home. The data are then securely delivered to a cloud-based platform. Surgeons can assess post-surgery recovery progress by comparing pre-operative mobility metrics captured by mymobility, with post-operative gait metrics collected by Persona IQ. Ultimately, the data from Persona IQ will be seamlessly integrated with pre-, intra- and post-operative data collected by the ZBEdge™ Connected Intelligence Suite and analyzed by OrthoIntel Orthopedic Intelligence Platform to provide surgeons with objective data as a supplement to patient care.
"Zimmer Biomet has a strong heritage of delivering revolutionary innovations that can transform the surgical experience and enable data-supported patient care," said Ivan Tornos, Chief Operating Officer of Zimmer Biomet. "The post-operative data captured by Persona IQ, together with the wealth of pre- and post-operative data collected by the mymobility platform, will provide surgeons with an exceptional level of objective and comparative data intelligence."
Persona IQ features the CANARY canturio™ te Tibial Extension proprietary implantable sensor developed by Canary Medical. The sensor technology was licensed by Zimmer Biomet through an exclusive partnership agreement with Canary Medical to develop first-to-market smart orthopedic implants to support remote monitoring and tracking of patient recovery metrics. The CANARY canturioTM te uses the same material and technology found in implanted cardiac devices such as pacemakers. The sensor is powered by a battery with a lifespan of up to 10 years, so patients will not need to charge the device. In addition, as an implanted technology, data is collected passively and does not rely on daily patient compliance to ensure information is captured by Persona IQ.
Persona IQ will be available to healthcare professionals and patients in the coming months. To learn more about Persona IQ and Persona The Personalized Knee, visit http://www.zimmerbiomet.com/personaiq. Please refer to the labeling for a complete list of warnings, precautions and contraindications.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
About Canary Medical
Canary Medical was conceived and created by a team of surgeons, medical device developers, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at lower costs, and (3) patients own their healthcare data and should be compensated for its use. Canary Medical's patented implant and data management ecosystem technology provides the vehicle to implement its vision. Canary is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.
For more information contact us at email@example.com or visit www.canarymedical.com. Follow Canary Medical on Twitter at @CanaryMedical.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
Source: Zimmer Biomet
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsZimmer Biomet Receives FDA Clearance for ROSA(R) Hip System for Robotically-Assisted Direct Anterior Total Hip Arthroplasty
Zimmer Biomet Announces New Appointments to Executive Leadership Team
Zimmer Biomet Receives FDA Clearance for ROSA(R) Partial Knee System for Robotically-Assisted Partial Knee Arthroplasty